Sweet Chemistry, a science-driven skincare company developing products based on regenerative medicine research, has raised $1.5 million in funding to expand production, address inventory challenges, and grow its presence in the beauty market. The round was led by Imaginary Ventures, with participation from Sandbridge Capital and beauty industry executive Carol Hamilton. The investment will support Sweet Chemistry’s efforts to increase manufacturing capacity, expand product availability, and accelerate brand growth.

Founded in 2023, Sweet Chemistry is a skincare company focused on combining cosmetic science with regenerative medicine research. The company was created in collaboration with Xylyx Bio, a biomedical technology company specializing in tissue engineering and organ rehabilitation. Sweet Chemistry uses research-derived bioactive ingredients called Matrikynes®, which are based on technology originally developed through Xylyx Bio’s regenerative medicine research.

The newly raised capital comes as Sweet Chemistry works to scale its operations and meet increasing consumer demand for its products. The company said the funding will help increase production capabilities, reduce product availability issues, and expand access to its science-focused skincare offerings.

Sweet Chemistry’s product development strategy is centered on applying discoveries from regenerative medicine to skincare. The company’s formulations feature Matrikynes®, proprietary peptide-based ingredients derived from extracellular matrix research. These ingredients were originally developed through biomedical research focused on tissue repair and regeneration before being adapted for cosmetic applications.

The company was founded by cosmetic chemist Alec Batis and biomedical engineer Dr. John O’Neill, who is also associated with Xylyx Bio’s research efforts. Sweet Chemistry’s founders aim to bring technologies inspired by regenerative medicine into the consumer skincare market by developing products designed around biological mechanisms involved in skin health.

Imaginary Ventures, which led the financing round, is a venture capital firm known for investing in consumer-focused companies across industries including beauty, retail, technology, and lifestyle. Its investment in Sweet Chemistry reflects growing investor interest in science-based consumer brands that combine product innovation with strong market opportunities.

Sandbridge Capital, which participated in the round, is a private investment firm focused on consumer brands and growth companies. The firm has invested in companies across beauty, fashion, retail, and consumer products, supporting brands as they expand their operations and market presence.

Beauty industry veteran Carol Hamilton also participated in the investment round. Hamilton has held leadership roles in major beauty companies, including serving as president of L’Oréal USA’s Luxe division, and has experience building and scaling global beauty brands. Her participation adds industry expertise as Sweet Chemistry works to grow its position in the skincare market.

Sweet Chemistry operates in a rapidly expanding skincare market where consumers are increasingly seeking products backed by scientific research and advanced ingredients. The company’s approach reflects a broader shift in the beauty industry toward biotechnology-inspired formulations, clinical testing, and ingredient transparency.

The company’s connection with Xylyx Bio provides access to research developed through the field of tissue engineering. Xylyx Bio’s work focuses on creating biomaterials and technologies for regenerative medicine, including applications related to organ repair and rehabilitation. Sweet Chemistry uses this scientific foundation to create skincare products based on bioactive signaling peptides.

Sweet Chemistry has positioned itself as a bridge between biomedical innovation and consumer beauty. Rather than relying solely on traditional cosmetic ingredients, the company focuses on translating scientific discoveries into products designed for everyday skincare routines.

The company’s funding follows an earlier $1 million raise announced in 2025 as investors showed increasing interest in science-backed beauty brands and peptide-based skincare products. Sweet Chemistry has raised a total of approximately $3.5 million across multiple funding rounds, according to publicly available company funding data.

The latest financing provides Sweet Chemistry with additional resources to strengthen its supply chain, increase manufacturing output, and expand brand awareness. The company plans to continue developing products based on its regenerative skincare approach while reaching more consumers through retail and direct-to-consumer channels.

As biotechnology continues influencing the beauty industry, companies combining scientific research with consumer products are attracting attention from investors and customers. Sweet Chemistry aims to capitalize on this trend by offering skincare products built around regenerative medicine concepts and advanced biological research.

With support from Imaginary Ventures, Sandbridge Capital, and Carol Hamilton, Sweet Chemistry plans to continue scaling its operations and advancing its mission of bringing regenerative science into modern skincare.

Related Articles